Celgene International Sárl Release: European Commission Grants VIDAZA(R) Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukaemia (AML)

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG): Celgene International Sàrl (Nasdaq:CELG) today announced that its cancer drug, VIDAZA (azacitidine), has been granted full marketing authorization by the European Commission for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: